Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Bertrand Routy

Showing results (71-80 of 126) with videos related to

Pageof 13
Sort By:
NPJ Precision Oncology|July 16, 2024
Antibiotics are associated with worse outcomes in lung cancer patients treated with chemotherapy and immunotherapyArielle Elkrief, Eder Orlando Méndez-Salazar, Jade Maillou, et al.
Neuro-Oncology Advances|April 7, 2023
Phase II multicenter trial combining nivolumab and radiosurgery for NSCLC and RCC brain metastasesPhilip Wong, Laura Masucci, Marie Florescu, et al.
Journal for Immunotherapy of Cancer|August 4, 2025
Improved survival in advanced melanoma patients treated with fecal microbiota transplantation using healthy donor stool in combination with anti-PD1: final results of the MIMic phase 1 trialDanial Khan Hadi, Kelly J Baines, Behnam Jabbarizadeh, et al.
Trials|December 13, 2025
Fecal microbiota transplantation to reduce immune activation in ART-treated people with HIV with low CD4/CD8 ratio: protocol for the single-blind, randomized, placebo-controlled Gutsy study (CIHR/CTN PT038)Stéphane Isnard, Carolina A Berini, Seema Nair Parvathy, et al.
Cell Reports|September 1, 2021
Combined single-cell transcriptional, translational, and genomic profiling reveals HIV-1 reservoir diversityGérémy Sannier, Mathieu Dubé, Caroline Dufour, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 17, 2021
A Uniform Computational Approach Improved on Existing Pipelines to Reveal Microbiome Biomarkers of Nonresponse to Immune Checkpoint InhibitorsFyza Y Shaikh, James R White, Joell J Gills, et al.
Journal of Translational Medicine|May 6, 2025
Computational analysis of whole slide images predicts PD-L1 expression and progression-free survival in immunotherapy-treated non-small cell lung cancer patientsAbdou Khadir Dia, Alona Kolnohuz, Sevinj Yolchuyeva, et al.
Oncoimmunology|September 16, 2020
Trial watch : the gut microbiota as a tool to boost the clinical efficacy of anticancer immunotherapyRomain Daillère, Lisa Derosa, Mélodie Bonvalet, et al.
Journal for Immunotherapy of Cancer|April 3, 2026
Targeting PAR-2 with a negative allosteric modulator increases tumor antigen presentation and potentiates anti-PD-1 immunotherapySamya Aouad, Maleck Kadiri, David Allard, et al.
Nature|July 8, 2026
Diet-microbiome synergy underlies obesity-associated immunotherapy efficacyLysanne Desharnais, Anikka Swaby, Meriem Messaoudene, et al.
Pageof 13

Showing results (71-80 of 126) with videos related to

Sort By:
Pageof 13
NPJ Precision Oncology|July 16, 2024
Antibiotics are associated with worse outcomes in lung cancer patients treated with chemotherapy and immunotherapyArielle Elkrief, Eder Orlando Méndez-Salazar, Jade Maillou, et al.
Neuro-Oncology Advances|April 7, 2023
Phase II multicenter trial combining nivolumab and radiosurgery for NSCLC and RCC brain metastasesPhilip Wong, Laura Masucci, Marie Florescu, et al.
Journal for Immunotherapy of Cancer|August 4, 2025
Improved survival in advanced melanoma patients treated with fecal microbiota transplantation using healthy donor stool in combination with anti-PD1: final results of the MIMic phase 1 trialDanial Khan Hadi, Kelly J Baines, Behnam Jabbarizadeh, et al.
Trials|December 13, 2025
Fecal microbiota transplantation to reduce immune activation in ART-treated people with HIV with low CD4/CD8 ratio: protocol for the single-blind, randomized, placebo-controlled Gutsy study (CIHR/CTN PT038)Stéphane Isnard, Carolina A Berini, Seema Nair Parvathy, et al.
Cell Reports|September 1, 2021
Combined single-cell transcriptional, translational, and genomic profiling reveals HIV-1 reservoir diversityGérémy Sannier, Mathieu Dubé, Caroline Dufour, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 17, 2021
A Uniform Computational Approach Improved on Existing Pipelines to Reveal Microbiome Biomarkers of Nonresponse to Immune Checkpoint InhibitorsFyza Y Shaikh, James R White, Joell J Gills, et al.
Journal of Translational Medicine|May 6, 2025
Computational analysis of whole slide images predicts PD-L1 expression and progression-free survival in immunotherapy-treated non-small cell lung cancer patientsAbdou Khadir Dia, Alona Kolnohuz, Sevinj Yolchuyeva, et al.
Oncoimmunology|September 16, 2020
Trial watch : the gut microbiota as a tool to boost the clinical efficacy of anticancer immunotherapyRomain Daillère, Lisa Derosa, Mélodie Bonvalet, et al.
Journal for Immunotherapy of Cancer|April 3, 2026
Targeting PAR-2 with a negative allosteric modulator increases tumor antigen presentation and potentiates anti-PD-1 immunotherapySamya Aouad, Maleck Kadiri, David Allard, et al.
Nature|July 8, 2026
Diet-microbiome synergy underlies obesity-associated immunotherapy efficacyLysanne Desharnais, Anikka Swaby, Meriem Messaoudene, et al.
Pageof 13